February 10, 2025
All-Antibody

Antibodies In Frontotemporal Dementia Neurotransmission And Synaptic

Anti-GluA3 antibodies in frontotemporal dementia: results on glutamatergic neurotransmission and synaptic failure.

Regardless of the good effort of the scientific group within the discipline, the pathogenesis of frontotemporal dementia (FTD) stays elusive. Lately, a task for autoimmunity and altered glutamatergic neurotransmission in triggering illness onset has been put ahead. We reported the presence of autoantibodies recognizing the GluA3 subunit of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in about 25% of FTD circumstances.

 

On this examine, we evaluated the mechanisms concerned in anti-GluA3 autoimmunity, via molecular/neurochemical analyses carried out on sufferers’ mind specimens with frontotemporal lobar degeneration-tau neuropathology. We then corroborated these ends in vivo in FTD sufferers with transcranial magnetic stimulation and glutamate, D-serine, and L-serine dosages within the cerebrospinal fluid and serum.

All-Antibody
All-Antibody

We noticed that GluA3 autoantibodies have an effect on glutamatergic neurotransmission, lowering glutamate launch and altering GluA3-containing α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor ranges. These alterations have been accompanied by adjustments of scaffolding proteins concerned in receptor synaptic retention/internalization.

 

The above outcomes have been confirmed by transcranial magnetic stimulation, suggesting a big impairment of oblique measures of glutamatergic neurotransmission in FTD sufferers in contrast with controls, with additional add-on dangerous impact in these FTD sufferers with anti-GluA3 antibodies. Lastly, FTD sufferers confirmed a big enhance of glutamate, D-serine, and L-serine ranges within the cerebrospinal fluid.

 

MOUSE ANTI HUMAN TNF ALPHA

MBS213345-02mg 0.2mg
EUR 935

MOUSE ANTI HUMAN TNF ALPHA

MBS213345-5x02mg 5x0.2mg
EUR 4045

Tumor necrosis factor alpha TNF-? (72 - 82), human (AA: Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg) (MW: 1171.33)

SP-86635-5 5 mg
EUR 343.2

Monoclonal Anti-Human Tumor Necrosis Factor-Alpha (TNF-alpha) IgG #1 aff. Pure

TNFA11-M 100 ug
EUR 578.4

Monoclonal Anti-Human Tumor Necrosis Factor-Alpha (TNF-alpha) IgG #2, aff. Pure

TNFA12-M 100 ug
EUR 578.4

Alpha 1-Antitrypsin, Human Plasma

A1AT15-N 1 mg
EUR 196.8

Alpha 2-Antiplasmin, Human Plasma

A2AP15-100 100 ug
EUR 196.8

Recombinant (E.Coli) Human p38 alpha/SAPK2 alpha

RP-675 1 ug
EUR 343.2

Rabbit Anti-Rat TNF-alpha Converting Enzyme (TACE) antiserum

TACE11-S 100 ul
EUR 548.4

Alpha 1-Antichymotrypsin , Human Plasma

A1CT15-N-100 100 ug
EUR 196.8

Rabbit Anti-Human alpha-Tubulin IgG

TUBA13-A 100 ul
EUR 578.4

Goat Anti-Human Tumor Necrosis Factor-Alpha (TNF-alpha) IgG #2, aff. Pure (neutralzing)

TNFA13-A 100 ul
EUR 578.4

Pig Tumor Necrosis Factor Alpha (TNF-a) ELISA Kit, 96 tests, Quantitative

9965 1 Kit
EUR 927.6

Recombinant (E.Coli) purified human Tumor Necrosis Factor-Alpha (TNF-alpha), biologically active

TNFA15-R-10 10 ug
EUR 270

Monoclonal Anti-Human alpha-Tubulin IgG

TUBA12-M 100 ul
EUR 578.4

Bovine Tumor necrosis factor alpha (TNF-A) ELISA Kit, 96 tests, Quantitative

9810 1 Kit
EUR 927.6

Canine Tumor Necrosis Factor alpha (TNF-a) ELISA Kit, 96 tests, Quantitative

10460 1 Kit
EUR 927.6

Rabbit Anti-human Topoisomerase II alpha (TOP2 alpha) IgG, aff pure

TOP2A11-A 100 ug
EUR 578.4

Chicken Anti-Human alpha 1 anti-trypsin IgG/Y

A1AT12-A 100 ul
EUR 578.4

Tumor necrosis factor alpha TNF-? (78-96) (human) (AA: His-Thr-Ile-Ser-Arg-Ile-Ala-Val-Ser-Tyr-Gln-Thr-Lys-Val-Asn-Leu-Leu-Ser-Ala) (MW: 2101.45)

SP-89730-1 1 mg
EUR 196.8

Rabbit Anti-Human p73 alpha antiserum # 2

P73A12-S 100 ul
EUR 548.4

Tumor necrosis factor alpha TNF-? (46-65) (human) (AA: Asn-Gln-Leu-Val-Val-Pro-Ser-Glu-Gly-Leu-Tyr-Leu-Ile-Tyr-Ser-Gln-Val-Leu-Phe-Lys) (MW: 2310.74)

SP-89728-1 1 mg
EUR 489.6

Rabbit Anti-Human Glutathione Transferase alpha (GST-alpha) antiserum

GSTA12-S 100 ul
EUR 548.4

Guinea pig Tumor Necrosis Factor Alpha (TNF-a) ELISA Kit, 96 tests, Quantitative

9870 1 Kit
EUR 927.6

Tumor necrosis factor alpha TNF-? (31 - 45), human (AA: Arg-Arg-Ala-Asn-Ala-Leu-Leu-Ala-Asn-Gly-Val-Glu-Leu-Arg-Asp) (MW: 1667.90)

SP-86636-1 1 mg
EUR 196.8

Human Alpha-Thrombin (human plasma), purified

TBNA16-N-100 100 ug
EUR 196.8

human Topoisomerase II alpha (TOP2 alpha) Control/blocking peptide

TOP2A11-P 100 ug
EUR 196.8

Recombinant Human Alpha-Synuclein

RP-847 20 ug
EUR 196.8

Rabbit Anti-Human Estrogen receptor alpha (ER-alpha) peptide IgG

ERA12-A 100 ug
EUR 578.4

Recombinant purified human TNF Receptor 2 (TNFR2/TNF-RII, Etannercept/TNF-R75, p75TNFR) protein (E.Coli, His-tag)

TNFR25-R-20 10 ug
EUR 343.2

Rabbit Anti-Human p73 alpha/beta antiserum # 1

P73A11-S 100 ul
EUR 548.4

Recombinant purified, human Interleukin-1 alpha (IL-1 alpha), active

IL1A15-R-10 10 ug
EUR 416.4

Monoclonal anti-human Alpha (FSH-Alpha), IgG clone 3 aff pure

FSHA12-M 1 mg
EUR 578.4

Goat Anti-human Alpha fetoprotein (AFP) IgG, pure

AFP13-A 1 mg
EUR 781.2

Goat Anti-Human Lutenizing Hormone Alpha (LH-Alpha) IgG aff pure

LHA13-A 1 mg
EUR 343.2

Tumor necrosis factor alpha TNF-? (10-36) (human) (AA: Asp-Lys-Pro-Val-Ala-His-Val-Val-Ala-Asn-Pro-Gln-Ala-Glu-Gly-Gln-Leu-Gln-Trp-Leu-Asn-Arg-Arg-Ala-Asn-Ala-Leu) (MW: 2996.41)

SP-89727-1 1 mg
EUR 270

Rabbit Anti-Rat TNF-alpha Converting Enzyme (TACE), IgG aff. Pure

TACE11-A 100 ug
EUR 578.4

Goat Anti-human Chorionic Gonadotropin Alpha (hCG-Alpha) IgG aff pure

HCGA13-A 1 mg
EUR 343.2

Rabbit Anti-Human HE2 alpha IgG #1, aff pure

HE2A11-A 100 ug
EUR 578.4

Rabbit Anti-Human p73 alpha/ IgG # 2, aff pure

P73A12-A 100 ug
EUR 578.4

Rabbit Anti-Human alpha-Tubulin IgG-HRP Conjugate

TUBA13-HRP 100 ul
EUR 518.4

Recombinant (E.Coli) Human Thyrostimulin Alpha

RP-595 10 ug
EUR 343.2

Rabbit Anti-Human alpha-Tubulin IgG-Biotin Conjugate

TUBA13-BTN 100 ul
EUR 562.8

Alpha 1-Antitrypsin (A1AT), Human protein control for WB

A1AT11-C 100 ul
EUR 343.2

Alpha 2-HS Glycoprotein, Human Plasma

A2HG15-N 1 mg
EUR 343.2

Alpha 2-Macroglobulin (A2M), Human Plasma

A2MG15-N 1 mg
EUR 196.8

Goat Anti-Human Alpha 1-Antitrypsin (A1AT) IgG, unlabeled

A1AT11-A 100 ul
EUR 489.6

Rabbit Anti-Human Resistin-Like protein alpha (RELM-alpha/FIZZ1) antiserum #2

RELMA12-S 100 ul
EUR 548.4

Chicken Anti-Human Alpha 2 Macroglobulin (A2M) IgG/Y

A2MG13-A 100 ul
EUR 578.4

Recombinant (E.Coli) Human Crystallin Alpha A

RP-611 20 ug
EUR 196.8

Recombinant (E.Coli) Human Crystallin Alpha B

RP-612 20 ug
EUR 196.8

Human Alpha Feto Protein (AFP) High Pure

AFP15-N 1 mg
EUR 854.4

Monoclonal Anti-Human Chorionic Gonadotropin Alpha (hCG-alpha) IgG #1, aff pure

HCGA11-M 1 mg
EUR 343.2

HUMAN ANTI TNF ALPHA (INFLIXIMAB BIOSIMILAR)

MBS226034-02mg 0.2mg
EUR 715

HUMAN ANTI TNF ALPHA (INFLIXIMAB BIOSIMILAR)

MBS226034-5x02mg 5x0.2mg
EUR 3045

Rabbit Anti-Human p73 alpha/beta IgG # 1, aff pure

P73A11-A 100 ug
EUR 578.4

Anti-Human TNF alpha

GWB-619378 1 mg Ask for price

Anti-Human TNF alpha

GWB-8F48ED 1 mL Ask for price

Anti-Human TNF-&alpha

GWB-BIG93C 500ug Ask for price

Monoclonal Anti-human Chronionic Gonadotropin Alpha (hCG-Alpha) IgG #2, caff pure

HCGA12-M 1 mg
EUR 343.2

Mouse Monoclonal Anti-human Alpha fetoprotein (AFP) (clone 1)

AFP11-M 1 mg
EUR 578.4

Mouse Monoclonal Anti-human Alpha fetoprotein (AFP) (clone 2)

AFP12-M 1 mg
EUR 578.4

Human Alpha Synuclein (A30P) Recombinant protein

SYN-A30P-R 50ug
EUR 315.6

Human Alpha Synuclein (A53T) Recombinant protein

SYN-A53T-R 50ug
EUR 315.6

Recombinant (E.Coli) Human Estrogen Receptor Alpha

RP-940 2 ug
EUR 416.4

Rabbit Anti-Human Alpha Defensin 4 (NP-4) antiserum #1

HDEFA41-S 100 ul
EUR 548.4

Rabbit Anti-Human Alpha Defensin 5 (NP-5),antiserum #1

HDEFA51-S 100 ul
EUR 548.4

Rabbit Anti-Human Alpha Defensin 6 (NP-6) antiserum #1

HDEFA61-S 100 ul
EUR 548.4

Recombinant (E.Coli) purified human Tumor Necrosis Factor-Alpha Variant (TNF-alpha variant, 151-aa), biologically active

TNFA16-R-10 10 ug
EUR 270

Human HE2 alpha Control/blocking peptide #1

HE2A11-P 100 ug
EUR 196.8

Human p73 alpha Control/blocking peptide #2

P73A12-P 100 ug
EUR 196.8

Sheep Anti-Human alpha 1 antichymotrypsin (ACT) IgG, aff pure

ACT11-A 100 ug
EUR 489.6

Rabbit Anti-Human GABAa Receptor alpha 1 (GAA1) Antiserum #1

GAA11-S 100 ul
EUR 548.4

Monoclonal anti-human Lutenizing Hormone Alpha (LH-Alpha) IgG, clone 2 aff pure

LHA12-M 1 mg
EUR 343.2

Recombinant (E.Coli) Human Casein Kinase 2 alpha

RP-666 3 ug
EUR 708

Recombinant (Sf9) Human Protein Kinase C alpha

RP-676 10 ug
EUR 343.2

Goat Anti-Human Alpha 1-Antitrypsin (A1AT) IgG, HRP conjugate

A1AT11-HRP 100 ul
EUR 489.6

Goat Anti-Human IgA (alpha chain sp.) IgG-Biotin Conjugate

10040 0.5 mg
EUR 242.4

Goat Anti-Ferret IgA (alpha), unlabeled

70519 0.5 mg
EUR 255.6

Purified Human alpha 1 antichymotrypsin (ACT) protein control for WB

ACT11-C 100 ul
EUR 343.2

Goat Anti-Human Alpha 1-Antitrypsin (A1AT) IgG, Biotin conjugate

A1AT11-BT 100 ul
EUR 489.6

Rabbit Anti-Human Core-binding factor alpha (CBFA1) antiserum #1

CBFA11-S 100 ul
EUR 548.4

Monoclonal Anti-Human alpha 1 antichymotrypsin (ACT) IgG, aff pure

ACT12-M 100 ug
EUR 578.4

Recombinant (E.Coli) Human Retinoid X Receptor Alpha

RP-1588 10 ug
EUR 270

Rabbit Anti-Rat Glutathione Transferase alpha (GST-alpha) antiserum

GSTA11-S 100 ul
EUR 548.4

Recombinant (P. Pastoris) Human collagen alpha-III

RP-920 10 mg
EUR 634.8

Human alpha 1 antichymotrypsin (ACT) (binds PSA to form PSA-ACT) >90%

ACT15-N-100 100 ug
EUR 315.6

Rabbit Anti-Human GABAa Receptor alpha 1 (166-269aa) IgG #1, aff pure

GAA14-A 100 ug
EUR 578.4

Human Alpha 1-Microglobulin A1M) High Pure (>98%)

A1M15-N-100 100 ug
EUR 270

Recombinant (E.Coli) Human Protein Phosphatase 2C alpha

RP-680 10 ug
EUR 270

Rabbit Anti-Human Resistin-Like protein alpha (RELM-alpha/FIZZ1) IgG #2, aff. Pure

RELMA12-A 100 ug
EUR 578.4

Elevated ranges of anti-dsDNA antibodies in immune complexes earlier than remedy with belimumab affiliate with scientific response in sufferers with systemic lupus erythematosus.

Immune complexes are of significance in systemic lupus erythematosus pathogenesis, and autoantibodies are believed to take part in immune advanced formation. Quantification of autoantibody ranges in circulating IC may be of prognostic worth.

 

  • A C1q-binding-eluting method was utilized to purify immune complexes from 55 belimumab-treated systemic lupus erythematosus sufferers throughout a 24-month follow-up. Autoantibodies in serum and in solubilized immune complexes have been quantified utilizing addressable laser bead immunoassay. We investigated whether or not ranges of autoantibodies in immune complexes affiliate with illness exercise and response to belimumab remedy.
  • Excessive baseline anti-double-stranded DNA and anti-histone ranges in immune complexes related to attainment of zero scores in scientific systemic lupus erythematosus illness exercise index 2000 through the 24-month follow-up (p = 0.003 and p = 0.048, respectively).
  • Low complement ranges related to excessive serum anti-double-stranded DNA and anti-ribosomal P ranges (p = 0.003 and p = 0.008, respectively) and excessive anti-double-stranded DNA (p = 0.002) however not anti-ribosomal P ranges in immune complexes. Anti-SSA/SSB serum ranges have been decrease in sufferers attaining lupus low illness exercise state at month 6; these associations have been stronger for corresponding immune advanced ranges.
  • Serum ranges of most autoantibodies had declined at month 3, whereas autoantibody ranges in immune complexes, apart from anti-double-stranded DNA, confirmed a extra gradual decline over 1-2 years. Serum anti-double-stranded DNA ranges decreased in all sufferers regardless of systemic lupus erythematosus illness exercise index 2000=Zero attainment, whereas immune advanced ranges decreased solely in achievers.
  • Immune advanced ranges of autoantibodies towards double-stranded DNA and the SSA/SSB advanced present extra particular associations with remedy consequence in contrast with serum ranges in belimumab-treated systemic lupus erythematosus sufferers. Characterization of autoantibody content material in circulating immune complexes might show helpful in remedy analysis in systemic lupus erythematosus and different immune complex-associated ailments.

No affiliation between anti-thyroidperoxidase antibodies and bipolar dysfunction: A examine within the Dutch Bipolar Cohort and a meta-analysis.

Thyroid autoimmunity has been related to bipolar dysfunction (BD). Nevertheless, outcomes from earlier research on the seroprevalence of anti-thyroid peroxidase antibodies (TPO-abs) in BD are inconsistent.

The purpose of the current examine is to research whether or not the seroprevalence and titer ranges of TPO-abs are associated to BD.TPO-abs have been measured in plasma samples of 760 sufferers with bipolar dysfunction, 261 first-degree family and 363 controls by enzyme-linked immunosorbent assay (ELISA).

To handle the methodological limitations of earlier research, we assessed scientific traits with a number of (self-reported) questionnaires to research whether or not TPO-abs positivity is said to specific scientific subgroups of BD sufferers. We carried out a further meta-analysis of seroprevalences of TPO-abs in BD sufferers together with information from current and former research.

Seroprevalence or titer ranges of TPO-abs didn’t considerably differ between sufferers with BD, their first-degree family, and controls. In BD sufferers, the prevalence of TPO-abs was unrelated to particular scientific elements, together with lithium use. Our meta-analysis of twelve research confirmed an total odds ratio of 1.3 (CI 95 %: 0.7-2.3; p = 0.30), reaffirming the absence of an affiliation of BD with TPO-abs. Within the largest examine of TPO-abs in BD so far, our findings point out that TPO-abs should not related to (the chance for) bipolar dysfunction.

 

Human IGF-BP4 Recombinant Protein

100-200 20 µg
EUR 196.35
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 26.1 kDa protein consisting of 238 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

Human IGF-BP4 Recombinant Protein

100-200S 5 µg
EUR 92.4
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 26.1 kDa protein consisting of 238 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

Recombinant Human IGF-BP4 Protein

PROTP22692-1 20ug
EUR 380.4
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 25.8 kDa protein consisting of 237 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

*Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc.

Human IGF-BP4 Recombinant Protein Lyophilized

IHUIGFBP4RLY5UG each
EUR 341
Description: Human IGF-BP4 Recombinant Protein Lyophilized

Human IGF-BP4 Recombinant Protein Lyophilized

MBS8432291-INQUIRE INQUIRE Ask for price

IGF-BP4 Recombinant Protein

40-318-0005mg 0.005 mg
EUR 311.1
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 25.8 kDa protein consisting of 237 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

IGF-BP4 Recombinant Protein

40-318-002mg 0.02 mg
EUR 437.1
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 25.8 kDa protein consisting of 237 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

Recombinant Human IGF BP3

HEGFP-0903 5ug Ask for price

Recombinant Human IGF BP5

HEGFP-0905 5ug Ask for price

Recombinant Human IGF BP7

HEGFP-0907 5ug Ask for price

human anti-human IGF-1 mAb(6E)

E4A09K04-6E 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

human anti-human IGF-1 mAb(8D)

E4A09K04-8D 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Rabbit Anti Human RIPK1 Monoclonal Clone IGF-18

IRBAHURIPK1IGF18C100UL each
EUR 496
Description: Rabbit Anti Human RIPK1 Monoclonal Clone IGF-18

Human IGF-BP7

MBS691503-0005mg 0.005mg
EUR 300

Human IGF-BP7

MBS691503-0025mg 0.025mg
EUR 450

Human IGF-BP7

MBS691503-5x0025mg 5x0.025mg
EUR 1725

Human IGF-BP6

MBS691832-0005mg 0.005mg
EUR 300

Human IGF-BP6

MBS691832-002mg 0.02mg
EUR 450

Human IGF-BP6

MBS691832-5x002mg 5x0.02mg
EUR 1725

Human IGF-BP3

MBS692057-0005mg 0.005mg
EUR 300

Human IGF-BP3

MBS692057-0025mg 0.025mg
EUR 450

Human IGF-BP3

MBS692057-5x0025mg 5x0.025mg
EUR 1725

Human IGF-BP2

MBS692085-0005mg 0.005mg
EUR 300

Human IGF-BP2

MBS692085-002mg 0.02mg
EUR 450

Human IGF-BP2

MBS692085-5x002mg 5x0.02mg
EUR 1725

Human IGF-BP1

MBS692092-0005mg 0.005mg
EUR 300

Human IGF-BP1

MBS692092-0025mg 0.025mg
EUR 450

Human IGF-BP1

MBS692092-5x0025mg 5x0.025mg
EUR 1725

Human IGF-BP5

MBS692152-0005mg 0.005mg
EUR 300

Human IGF-BP5

MBS692152-0025mg 0.025mg
EUR 450

Human IGF-BP5

MBS692152-5x0025mg 5x0.025mg
EUR 1725

Human IGF-1

MBS691641-01mg 0.1mg
EUR 300

Human IGF-1

MBS691641-05mg 0.5mg
EUR 450

Human IGF-1

MBS691641-5x05mg 5x0.5mg
EUR 1725

Human IGF-2

MBS691655-001mg 0.01mg
EUR 300

Human IGF-2

MBS691655-005mg 0.05mg
EUR 450

Human IGF-2

MBS691655-5x005mg 5x0.05mg
EUR 1725

IGF-BP3, Human

HY-P7020 10ug
EUR 280.8

IGF-BP5, Human

HY-P7021 50ug
EUR 721.2

IGF-BP3, human

RC216-12B3 5ug
EUR 125.26

Anti-Human IGF-BP1 Antibody

101-M457 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP2 Antibody

101-M458 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP3 Antibody

101-M459 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP5 Antibody

101-M461 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP6 Antibody

101-M462 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP7 Antibody

101-M463 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP3 Antibody

102-P144 100 µg
EUR 245.7
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP5 Antibody

102-P232 100 µg
EUR 245.7
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP7 Antibody

102-P233 100 µg
EUR 245.7
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

IGF BP3 antibody

70R-IR022 50 ug
EUR 312
Description: Affinity purified Rabbit polyclonal IGF BP3 antibody

IGF BP5 antibody

70R-IR023 50 ug
EUR 312
Description: Affinity purified Rabbit polyclonal IGF BP5 antibody

IGF BP7 antibody

70R-IR024 50 ug
EUR 312
Description: Affinity purified Rabbit polyclonal IGF BP7 antibody

IGF BP7 antibody

MBS535700-005mg 0.05mg
EUR 465

IGF BP7 antibody

MBS535700-5x005mg 5x0.05mg
EUR 1945

IGF BP3 antibody

MBS535722-005mg 0.05mg
EUR 465

IGF BP3 antibody

MBS535722-5x005mg 5x0.05mg
EUR 1945

IGF BP5 antibody

MBS535907-005mg 0.05mg
EUR 465

IGF BP5 antibody

MBS535907-5x005mg 5x0.05mg
EUR 1945

IGF-1, Human

HY-P7018 10ug
EUR 129.6

IGF-2, Human

HY-P7019 100ug
EUR 432

IGF-1 (Human)

MBS352114-1Bottle 1Bottle
EUR 350

IGF-1 (Human)

MBS352114-5x1Bottle 5x1Bottle
EUR 1490

IGF-1 (Human)

MBS352116-01mL 0.1mL
EUR 450

IGF-1 (Human)

MBS352116-5x01mL 5x0.1mL
EUR 1950

IGF-2 (Human)

MBS352118-1Bottle 1Bottle
EUR 350

IGF-2 (Human)

MBS352118-5x1Bottle 5x1Bottle
EUR 1490

IGF-1, human

RC216-12 1mg
EUR 451.5

Recombinant Human LR3 IGF-I/IGF-1

PH2031-.01 10ug
EUR 208
Description: Peptides & Proteins|Recombinant Proteins

Recombinant Human LR3 IGF-I/IGF-1

PH2031-.1 10X10ug
EUR 496
Description: Peptides & Proteins|Recombinant Proteins

Anti-Human IGF-1 Antibody

101-M454 100 µg
EUR 399
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity.

Anti-Human IGF-2 Antibody

101-M456 100 µg
EUR 399
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity.

Anti-Human IGF-1 Antibody

102-P28 100 µg
EUR 245.7
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity.

Anti-Human IGF-2 Antibody

102-P29 100 µg
EUR 245.7
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity.

Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2)

MBS635918-005mg 0.05mg
EUR 495

Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2)

MBS635918-5x005mg 5x0.05mg
EUR 2075

Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2)

MBS650945-001mg 0.01mg
EUR 390

Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2)

MBS650945-005mg 0.05mg
EUR 540

Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2)

MBS650945-5x005mg 5x0.05mg
EUR 2275

Antibody for Human IGF-1

SPC-699D-A565 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 565.

Antibody for Human IGF-1

SPC-699D-A633 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 633.

Antibody for Human IGF-1

SPC-699D-A655 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 655.

Antibody for Human IGF-1

SPC-699D-A680 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 680.

Antibody for Human IGF-1

SPC-699D-A700 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 700.

Antibody for Human IGF-1

SPC-699D-APCCY7 0.1mg
EUR 565.2
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to APC/Cy7.

Antibody for Human IGF-1

SPC-699D-DY350 0.1mg
EUR 496.8
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 350.

Antibody for Human IGF-1

SPC-699D-DY405 0.1mg
EUR 483.6
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 405.

Antibody for Human IGF-1

SPC-699D-DY488 0.1mg
EUR 471.6
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 488.

Antibody for Human IGF-1

SPC-699D-DY594 0.1mg
EUR 474
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 594.

Antibody for Human IGF-1

SPC-699D-DY633 0.1mg
EUR 468
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 633.

Antibody for Human IGF-1

SPC-699D-P594 0.1mg
EUR 488.4
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to PE/ATTO 594.

Antibody for Human IGF-1

SPC-699D-STR 0.1mg
EUR 477.6
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Streptavidin.

Human IGF-I

GWB-4FCE40 0.1 mg Ask for price

Human IGF-I

MBS400113-INQUIRE INQUIRE Ask for price

Human IGF-I

MBS400117-01mg 0.1mg
EUR 170

Human IGF-I

MBS400117-05mg 0.5mg
EUR 235

Human IGF-I

MBS400117-10mg 10mg
EUR 1595

Human IGF-I

MBS400117-1mg 1mg
EUR 305

Human IGF-I

MBS400117-5mg 5mg
EUR 940

Leave a Reply

Your email address will not be published. Required fields are marked *